www.abbviepro.com Open in urlscan Pro
2606:4700:4400::ac40:90de Public Scan

Back to summary

Submitted URL:
http://skyrizi.co.uk/
Effective URL:
https://www.abbviepro.com/gb/en/immunology/dermatology/products/skyrizi.html
Submission: On December 13 via api (December 13th 2023, 2:18:47 pm UTC) from TR — Scanned from DE

Form analysis
0 forms found in the DOM

Text Content

×
Immunology:
* Dermatology
* Rheumatology
* Gastroenterology

Our other therapy areas
Our other therapy areas
* Neuroscience Focus Areas
* Oncology
* Contact Us
* Local Sitemap (DO NOT MODIFY)

* Report Adverse Event
* Contact us

{%itemName%}
{%brandMenuItems%}

{%itemName%} {%arrowSpan%}
{%subBrandMenuItems%}

{%itemName%} {%arrowSpan%}
{%productMenuItems%}

{%itemKeyName%} {%itemBadges%} {%arrowSpan%}
{%selfProduct%}

{%itemName%}

{%languageSelectorLabel%}

{%activeLanguage%}
{%countries%}

{%allMenuItem%}
{%countryInfo%}
{%languages%}

This website is for UK Healthcare Professionals only

* Products

SKYRIZI DOSING GUIDE
SKYRIZI PRESCRIBING INFORMATION
ADALIMUMAB PRESCRIBING INFORMATION

PLAQUE PSORIASIS: SKYRIZI (RISANKIZUMAB) IS INDICATED FOR THE TREATMENT OF
MODERATE TO SEVERE PLAQUE PSORIASIS IN ADULTS WHO ARE CANDIDATES FOR SYSTEMIC
THERAPY.1

PSORIATIC ARTHRITIS: SKYRIZI ALONE OR IN COMBINATION WITH METHOTREXATE, FOR
THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS IN ADULTS WHO HAVE HAD AN INADEQUATE
RESPONSE OR WHO HAVE BEEN INTOLERANT TO ONE OR MORE
DISEASE-MODIFYING ANTIRHEUMATIC DRUGS.1

* Home
* Efficacy
* Dosing
* Safety Profile
* Study Designs
* Expert Perspectives

Video library Peer podcasts
* Events Calendar
* Contact Us

PLAQUE PSORIASIS

Click for NICE recommendation
Click for SMC acceptance

Links will take you to a third party site

PSORIATIC ARTHRITIS

Click for NICE recommendation
Click for SMC acceptance

--------------------------------------------------------------------------------

SKYRIZI - PRODUCT INFORMATION

DURABILITY

Durable efficacy in psoriasis for 4.9 years6

SKYRIZI efficacy vs secukinumab7

Durable SKYRIZI efficacy vs. ustekinumab8,9

SKYRIZI efficacy vs adalimumab10

Durable efficacy in psoriatic arthritis through to 52 weeks11

See SKYRIZI efficacy data

SIMPLICITY

Only 4 injections per year (after 2 initiations injections)1

Simple every 12 week maintenance dosing after initial starter dosing1

A consistent dosing regimen across all SKYRIZI patients1

Nurse support for your patients

See SKYRIZI dosing information

SAFETY PROFILE

Consistent safety profile in psoriasis for >5 years6

A similar safety profile to secukinumab, ustekinumab and adalimumab in psoriasis
Phase III clinical trials.7-10

Demonstrated safety profile in psoriatic arthritis through to 52 weeks.11

No contraindications/warnings for Crohn's disease and ulcerative colitis‡1

See SKYRIZI safety profile

‡Contraindications include hypersensitivity to the active substance or to any of
the excipients and clinically important active infections e.g. active
tuberculosis.

--------------------------------------------------------------------------------

SIMPLE DOSING REGIME

WITH THE SKYRIZI 150MG PEN

15 SECOND INJECTION TIME12

EXPERT PERSPECTIVES

View expert perspectives on SKYRIZI's efficacy data, dosing regimen and safety
profile.

--------------------------------------------------------------------------------

SKYRIZI MODE OF ACTION: TREAT A CAUSE, NOT AN EFFECT. TARGET A KEY DRIVER OF
PSORIATIC INFLAMMATION.13-17

SKYRIZI binds with high specificity to the p19 subunit of IL-23, causing
prolonged down-regulation of pathogenetic Th17 cells, leading to a reduction of
proinflammatory cytokines.13-17

Adapted from Kofoed K et al. 2015.14

DR KAVE SHAMS DISCUSSES THE MODE OF ACTION OF SKYRIZI AND THE IL-23/TH17 PATHWAY

SKYRIZI MODE OF ACTION ANIMATION

Dr Kave Shams discusses the mode of action of SKYRIZI and the IL-23/Th17 pathway

Video Player is loading.
Play Video
Play
Mute

Current Time 0:00
/
Duration 5:05
Loaded: 3.23%

0:00
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -5:05
1x
Playback Rate

Chapters
* Chapters

Descriptions
* descriptions off, selected

Captions
* captions settings, opens captions settings dialog
* captions off, selected

Audio Track
* en (Main), selected

Picture-in-PictureFullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

TextColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentBackgroundColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparentWindowColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque
Font Size50%75%100%125%150%175%200%300%400%Text Edge
StyleNoneRaisedDepressedUniformDropshadowFont FamilyProportional
Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall
Caps
Reset restore all settings to the default valuesDone
Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or
activating the close button.

Play Video

SKYRIZI mode of action animation

Video Player is loading.
Play Video
Play
Mute

Current Time 0:00
/
Duration 2:48
Loaded: 5.86%

0:00
Stream Type LIVE
Seek to live, currently behind liveLIVE
Remaining Time -2:48
1x
Playback Rate

Chapters
* Chapters

Descriptions
* descriptions off, selected

Captions
* captions settings, opens captions settings dialog
* captions off, selected

Audio Track
* en (Main), selected

Picture-in-PictureFullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or
activating the close button.

Play Video

--------------------------------------------------------------------------------

I WANT TO FIND OUT MORE ABOUT SKYRIZI

Explore efficacy data

--------------------------------------------------------------------------------

I WANT TO RECEIVE MORE INFORMATION ABOUT SKYRIZI

Contact AbbVie

--------------------------------------------------------------------------------

REFERENCES

1. SKYRIZI: Summary of Product Characteristics.
2. © NICE 2019 Risankizumab for treating moderate to severe psoriasis.
Available from https://www.nice.org.uk/guidance All rights reserved. NICE
is prepared for the National Health Service in England. All NICE guidance
is subject to regular review and may be updated or withdrawn. NICE accepts
no responsibility for the use of its content in this product/publication.
3. Scottish Medicines Consortium. SMC2196.
http://www.scottishmedicines.org.uk/medicines-advice.
4. © NICE 2022 Risankizumab for treating active psoriatic arthritis. Available
from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of
rights. NICE guidance is prepared for the National Health Service in
England. All NICE guidance is subject to regular review and may be updated
or withdrawn. NICE accepts no responsibility for the use of its content in
this product/publication.
5. Scottish Medicines Consortium. SMC2459.
https://www.scottishmedicines.org.uk/medicines-advice.
6. Papp K, et al. Long-Term Safety and Efficacy of Risankizumab for the
Treatment of Moderate-to-Severe Plaque Psoriasis: A 4.5-Year Interim
Analysis of the LIMMitless Open-Label Extension Trial. Presented at the
31st European Academy of Dermatology and Venereology Congress, (EADV 2022),
7–10 September 2022, Milan, Italy.
7. Warren et al., Risankizumab vs Secukinumab in Patients with
Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD
2020.
8. Gordon KB et al. Lancet 2018;392: 650-661.
9. Strober B, et al. Poster 1714, presented at the 28th European Academy of
Dermatology and Venereology (EADV) Congress, 9 13 October 2019, Madrid,
Spain.
10. Reich K et al. Lancet 2019;394: 576-586.
11. Kristensen LE et al. Efficacy and Safety of Risankizumab for Active
Psoriatic Arthritis: 52-Week Results From the KEEPsAKE 1 and KEEPsAKE 2
Trials. Oral presentation EADV 30th Congress 2021 - Anniversary Edition 29
Sept – 2 Oct 2021.
12. SKYRIZI Patient Information Leaflet - May 2021.
13. Gooderham MJ et al. J Eur Acad Dermatol Venereol 2018; 32(7):1111-1119.

14. Kofoed K et al. Acta Derm Venereol. 2015;95(2):133-139.
15. Gaffen SL et al. Nat Rev Immunol 2014; 14(9): 585-600.
16. Girolomoni G et al. J Eur Acad Dermatol Venereol 2017; 31(1): 1616-1626.
17. Lynde CW et al. J Am Acad Dermatol 2014; 71(1): 141-150.

UK-RISN-230157. Date of preparation: July 2023.

SKYRIZI PRESCRIBING INFORMATION
ADALIMUMAB PRESCRIBING INFORMATION

--------------------------------------------------------------------------------

SKYRIZI® (risankizumab) is indicated for the treatment of moderate to severe
plaque psoriasis in adults who are candidates for systemic therapy.1
SKYRIZI® (risankizumab) alone or in combination with methotrexate, is indicated
for the treatment of active psoriatic arthritis in adults who have had an
inadequate response or who have been intolerant to one or more disease-modifying
antirheumatic drugs.1
The recommended dose of SKYRIZI is 150mg administered by subcutaneous injection
at Week 0, Week 4, and every 12 weeks thereafter.
SKYRIZI is intended for use under the guidance and supervision of a physician
experienced in the diagnosis and treatment of psoriasis.
Some patients may not be suitable for SKYRIZI. You are advised to read the
Prescribing Information (which can be found on tab above). Please also refer to
the SKYRIZI Summary of Product Characteristics for important information
including special warnings/precautions for use and summary of adverse reactions.
Study design information can be found on the Study Design page.

Adverse events should be reported. Reporting forms and information can be found
at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com

IMPORTANT SAFETY INFORMATION

OUR THERAPY AREAS

--------------------------------------------------------------------------------

Immunology
Oncology
Neuroscience

ADDITIONAL INFO

--------------------------------------------------------------------------------

Privacy Notice
Terms of Use
Contact us

Adverse events should be reported. Reporting forms and information can be found
at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in
the Google Play or Apple App Stores. Adverse events should also be reported to
AbbVie on GBPV@abbvie.com

THIS WEBSITE IS FOR UK HEALTHCARE PROFESSIONALS ONLY

UK-ABBV-230225. Date of preparation June 2023. This website has been developed
and funded by AbbVie Ltd.

Leaving Site

You are now leaving the AbbVie Pro Portal and being re-directed to an external
website which is not under the control of AbbVie. AbbVie is not responsible for
content of any such site or any further links from such site.

Do you wish to continue?

No
Yes
* www.abbvie.com
* preview.abbviepro.com
* www.abbviepro.com
* www-p65.abbviepro.com

WELCOME

To direct you to the most appropriate information, please confirm:

I am a UK Healthcare Professional.

This AbbVie website is intended for UK Healthcare Professionals only and
contains promotional content.

Confirm

I am a member of the public based in the UK

Continue

Report adverse events (healthcare professionals in the UK)

Adverse events should be reported. Reporting forms and information can be found
at https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in
the Google Play or Apple App Stores.

Adverse events should also be reported to AbbVie at GBPV@abbvie.com

Reporting of side effects (patients and public in the UK)

If you get any side effects, talk to your doctor, pharmacist or nurse. This
includes any possible side effects not listed in the package leaflet. You can
also report side effects directly via the Yellow Card Scheme at
https://yellowcard.mhra.gov.uk or via the MHRA Yellow Card app, available in the
Google Play or Apple App Stores. Adverse events should also be reported to
AbbVie at GBPV@abbvie.com

By reporting side effects you can help provide more information on the safety of
this medicine.

For medicines with black triangle:

▼ means the medicine is subject to additional monitoring. This will allow quick
identification of new safety information. You can help by reporting any side
effects you may get. See https://yellowcard.mhra.gov.uk for how to report side
effects or via the MHRA Yellow Card app, available in the Google Play or Apple
App Stores. Adverse events should also be reported to AbbVie at GBPV@abbvie.com

UK-ABBV-230223. Date of preparation: June 2023

Cookie-Präferenzen

WIR SCHÄTZEN IHRE PRIVATSPHÄRE SEHR

This site uses cookies and related technologies, as described in our privacy
notice, for purposes that may include site operation, analytics, or enhanced
user experience. You may choose to consent to our use of these technologies, or
manage your own preferences.
Accept & Proceed Decline & Proceed
Von:

www.abbviepro.com Open in urlscan Pro 2606:4700:4400::ac40:90de Public Scan

Form analysis 0 forms found in the DOM

Text Content

www.abbviepro.com Open in urlscan Pro
2606:4700:4400::ac40:90de Public Scan

Form analysis
0 forms found in the DOM